Phase I trial of ⁹⁰Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation

References

• Shipp M A, Abeloff M D, Antman K H, Carroll G, Hagenbeek A, Loeffler M. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive Non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999; 17: 423–429
   PubMed Web of Science ®Google Scholar
• Vose J M, Zhang M J, Rowlings P A, Lazarus H M, Bolwell B J, Freytes C O. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406–413
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz A D, Nimer S D, Portlock C, Straus D, Noy A. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684–3688
   PubMed Web of Science ®Google Scholar
• Moskowitz C H, Bertino J R, Glassman J R, Hedrick E E, Hunte S, Coady-Lyons N. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776–3785
   PubMed Web of Science ®Google Scholar
• Hamlin P A, Zelenetz A D, Kewalramani T, Qin J, Satagopan J M, Verbel D. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102: 1989–1996
   PubMed Web of Science ®Google Scholar
• Rapoport A P, Rowe J M, Kouides P A, Duerst R A, Abbond C N, Liesveld J L. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 1993; 11: 2351–2361
   PubMed Web of Science ®Google Scholar
• Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli A, Sebban C. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998; 16: 3264–3269
   PubMed Web of Science ®Google Scholar
• Corradini P, Ladetto M, Zallio F, Astulfi M, Rizzo E, Sametti S. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004; 22: 1460–1468
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Schiegnitz E, Forstpointer R, Wandt H, Freund M. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 2667–2674
   PubMed Web of Science ®Google Scholar
• Schouten H C, Qian W, Kvaloy S, Porcelline A, Hagberg H, Johnsen H E. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Nimer S D, Zelenetz A D, Malhotra S, Qin J, Yahalom J. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 32: 673–679
   PubMed Web of Science ®Google Scholar
• Kuittinen T, Wiklund T, Remes K, Elonen E, Lehtinen T, Kuiltinen O. Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a nation-wide survey. Eur J Haematol 2005; 75: 199–205
   PubMed Web of Science ®Google Scholar
• Vose J M, Bierman P J, Anderson J R, Kessinger A, Pierso J, Nelson J. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992; 80: 2142–2148
   PubMed Web of Science ®Google Scholar
• Paltiel O, Rubinstein C, Or R, Nagler A, Gordon L, Deutsch L. Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplant 2003; 31: 565–569
   PubMed Web of Science ®Google Scholar
• Davies A J, Rohatiner A Z, Howell S, Britton K E, Owens S E, Micallef I N. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1469–1479
   PubMed Web of Science ®Google Scholar
• Gordon L I, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 2004; 5: 98–101
   PubMedGoogle Scholar
• Gordon L I, Molina A, Witzig T, Emmanouilides M, Raubtischek A, Darif M. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103: 4429–4431
   PubMed Web of Science ®Google Scholar
• Horning S J, Younes A, Jain V, Kroll S, Lucas J, Podoloff D. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005; 23: 712–719
   PubMed Web of Science ®Google Scholar
• Schilder R, Molina A, Bartlett N, Witzig T, Gordon L, Murray J. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 2004; 19: 478–481
   PubMed Web of Science ®Google Scholar
• Vose J M, Wahl R L, Saleh M, Rohatines A Z, Knox S J, Radford J A. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000; 18: 1316–1323
   PubMed Web of Science ®Google Scholar
• Witzig T E, Flinn I W, Gordon L I, Emmanonilides C, Czuczman M S, Saleh M N. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262–3269
   PubMed Web of Science ®Google Scholar
• Fisher R I, Kaminski M S, Wahl R L, Knox S J, Zelenetz A D, Vose J M. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 7565–7573
   PubMed Web of Science ®Google Scholar
• Wiseman G A, Witzig T E. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2005; 20: 185–188
   PubMed Web of Science ®Google Scholar
• Zevalin (Ibritumomab Tiuxetan) Prescribing Information. Biogen Idec, Cambridge, MA 2005
   Google Scholar
• Jacobs S A, Vidnovic N, Joyce J, McCook B, Torok F, Avril N. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res 2005; 11: 7146s–7150s
   PubMed Web of Science ®Google Scholar
• Kaminski M S, Estes J, Zasadny K R, Francis I R, Ross C W, Tuck M. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259–1266
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J ML. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Cox D R. regression models and life tables. J R Stat Soc B 1972; 34: 187–220
   Google Scholar
• Kaya H, Keung Y K, Case D, Cruz J M, Perry J J, Radford J E. Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2002; 8: 544–549
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czuczman M S, Williams M E. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Brugger W, Hirsch J, Grunebach F, Repp R, Brossart P, Vogel W. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 2004; 15: 1691–1698
   PubMed Web of Science ®Google Scholar
• Khouri I F, Saliba R M, Hosing C, Okoroji G J, Acholonu S, Anderini P. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 2240–2247
   PubMed Web of Science ®Google Scholar
• Emmanouilides C, Witzig T E, Gordon L I, Vo K, Wiseman G, Flinn I. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 629–636
   PubMed Web of Science ®Google Scholar
• Gregory S A, Leonard J P, Vose J M, Zelenetz A D, Horning S J, Know S J. Superior outcomes associated with earlier use: experience with tositumomab and iodine I 131 tositumomab in 1,177 patients (pts) with low-grade, follicular, and transformed non-Hodgkin's lymphoma (NHL) (Abstract 6561). Proc Am Soc Clin Oncol 2005; 23: 575s
   Web of Science ®Google Scholar
• Kaminski M S, Tuck M, Estes J, Kolstad A, Ross C N, Zasadny K. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441–449
   PubMed Web of Science ®Google Scholar
• Shipley D L, Greco F A, Spigel D R, Edwards D, Mayfield M, Yost K. Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: update of a Minnie Pearl Cancer Research Network phase II trial (Abstract 6577). Proc Am Soc Clin Oncol 2005; 23: 579s
   Web of Science ®Google Scholar
• Sweetenham J W, Dicke K, Arcaroli J, Kogel K, Rana T M, Rice L L. Efficacy and safety of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients with untreated low-grade follicular non-Hodgkin's lymphoma (Abstract 2633) (abstr). Blood 2004; 104: 720a
   Web of Science ®Google Scholar
• Ansell S M, Schilder R J, Pieslor P C, Gordon L, Emmanouilides C, Vo K. Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. Clin Lymphoma 2004; 5: 202–204
   PubMedGoogle Scholar